227 related articles for article (PubMed ID: 31628517)
1. Comparison of calcineurin inhibitors in combination with conventional methotrexate, reduced methotrexate, or mycophenolate mofetil for prophylaxis of graft-versus-host disease after umbilical cord blood transplantation.
Yoshida S; Ohno Y; Nagafuji K; Yoshimoto G; Sugio T; Kamimura T; Ohta T; Takase K; Henzan H; Muta T; Iwasaki H; Ogawa R; Eto T; Akashi K; Miyamoto T
Ann Hematol; 2019 Nov; 98(11):2579-2591. PubMed ID: 31628517
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.
Kharfan-Dabaja M; Mhaskar R; Reljic T; Pidala J; Perkins JB; Djulbegovic B; Kumar A
Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010280. PubMed ID: 25061777
[TBL] [Abstract][Full Text] [Related]
3. Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil.
Terakura S; Wake A; Inamoto Y; Murata M; Sakai R; Yamaguchi T; Takahashi S; Uchida N; Onishi Y; Ohashi K; Ozawa Y; Kanamori H; Yamaguchi H; Fukuda T; Ichinohe T; Takanashi M; Atsuta Y; Teshima T
Bone Marrow Transplant; 2017 Mar; 52(3):423-430. PubMed ID: 27941766
[TBL] [Abstract][Full Text] [Related]
4. Comparison of cyclosporine and tacrolimus combined with mycophenolate mofetil in prophylaxis for graft-versus-host disease after reduced-intensity umbilical cord blood transplantation.
Miyamoto T; Takashima S; Kato K; Takase K; Yoshimoto G; Yoshida S; Henzan H; Osaki K; Kamimura T; Iwasaki H; Eto T; Teshima T; Nagafuji K; Akashi K
Int J Hematol; 2017 Jan; 105(1):92-99. PubMed ID: 27686673
[TBL] [Abstract][Full Text] [Related]
5. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
Chhabra S; Liu Y; Hemmer MT; Costa L; Pidala JA; Couriel DR; Alousi AM; Majhail NS; Stuart RK; Kim D; Ringden O; Urbano-Ispizua A; Saad A; Savani BN; Cooper B; Marks DI; Socie G; Schouten HC; Schoemans H; Abdel-Azim H; Yared J; Cahn JY; Wagner J; Antin JH; Verdonck LF; Lehmann L; Aljurf MD; MacMillan ML; Litzow MR; Solh MM; Qayed M; Hematti P; Kamble RT; Vij R; Hayashi RJ; Gale RP; Martino R; Seo S; Hashmi SK; Nishihori T; Teshima T; Gergis U; Inamoto Y; Spellman SR; Arora M; Hamilton BK
Biol Blood Marrow Transplant; 2019 Jan; 25(1):73-85. PubMed ID: 30153491
[TBL] [Abstract][Full Text] [Related]
6. Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation.
Bejanyan N; Rogosheske J; DeFor TE; Lazaryan A; Arora M; Holtan SG; Jacobson PA; MacMillan ML; Verneris MR; Blazar BR; Weisdorf DJ; Wagner JE; Brunstein CG
Biol Blood Marrow Transplant; 2016 Nov; 22(11):2025-2030. PubMed ID: 27519278
[TBL] [Abstract][Full Text] [Related]
7. Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia.
Terakura S; Kuwatsuka Y; Sugita J; Takahashi S; Ozawa Y; Ozeki K; Yoshioka S; Nakamae H; Kawakita T; Sawa M; Morishige S; Najima Y; Katsuoka Y; Sakaida E; Kouzai Y; Kimura T; Ichinohe T; Fukuda T; Atsuta Y; Murata M; Teshima T
Int J Hematol; 2021 Jun; 113(6):840-850. PubMed ID: 33611725
[TBL] [Abstract][Full Text] [Related]
8. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation.
Hamilton BK; Rybicki L; Dean R; Majhail NS; Haddad H; Abounader D; Hanna R; Sobecks R; Duong H; Hill BT; Copelan E; Bolwell B; Kalaycio M
Am J Hematol; 2015 Feb; 90(2):144-8. PubMed ID: 25353395
[TBL] [Abstract][Full Text] [Related]
9. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
[TBL] [Abstract][Full Text] [Related]
10. Minimum-Dose, Short-Term Methotrexate With Tacrolimus for Graft-vs-Host Disease Prophylaxis Following Unrelated Cord Blood Transplantation in Adults: A Retrospective Analysis at a Single Institution.
Iino M; Sato T; Sakamoto Y
Transplant Proc; 2021; 53(1):396-404. PubMed ID: 33308840
[TBL] [Abstract][Full Text] [Related]
11. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation.
Bolwell B; Sobecks R; Pohlman B; Andresen S; Rybicki L; Kuczkowski E; Kalaycio M
Bone Marrow Transplant; 2004 Oct; 34(7):621-5. PubMed ID: 15300236
[TBL] [Abstract][Full Text] [Related]
12. Reduced dose of MTX for GVHD prophylaxis promotes engraftment and decreases non-relapse mortality in umbilical cord blood transplantation.
Shiratori S; Ohigashi H; Takahashi S; Ara T; Goto H; Nakagawa M; Sugita J; Onozawa M; Kahata K; Endo T; Hashimoto D; Teshima T;
Ann Hematol; 2020 Mar; 99(3):591-598. PubMed ID: 32006152
[TBL] [Abstract][Full Text] [Related]
13. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].
Wang J; Song X; Zhang W; Tong S; Hou J; Chen L; Lou J; Li H; Ding X; Min B
Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(8):507-10. PubMed ID: 12133492
[TBL] [Abstract][Full Text] [Related]
14. The combination of cyclosporine and mycophenolate mofetil is less effective than cyclosporine and methotrexate in the prevention of acute graft-versus host disease after stem-cell transplantation from unrelated donors.
Yerushalmi R; Shem-Tov N; Danylesko I; Shouval R; Nagler A; Shimoni A
Am J Hematol; 2017 Mar; 92(3):259-268. PubMed ID: 28052467
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of the dosage of methotrexate combined with tacrolimus for graft-versus-host disease prophylaxis after cord blood transplantation.
Adachi M; Yokota D; Hirata H; Koyauchi K; Dohtan S; Oka S; Sakamoto N; Takaba M; Takemura T; Nagata Y; Naito K; Ono T
Int J Hematol; 2021 Aug; 114(2):252-262. PubMed ID: 34086252
[TBL] [Abstract][Full Text] [Related]
16. Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan.
Isobe M; Konuma T; Masuko M; Uchida N; Miyakoshi S; Sugio Y; Yoshida S; Tanaka M; Matsuhashi Y; Hattori N; Onizuka M; Aotsuka N; Kouzai Y; Wake A; Kimura T; Ichinohe T; Atsuta Y; Yanada M;
Ann Hematol; 2021 Jul; 100(7):1849-1861. PubMed ID: 33624134
[TBL] [Abstract][Full Text] [Related]
17. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings.
Piñana JL; Valcárcel D; Fernández-Avilés F; Martino R; Rovira M; Barba P; Martínez C; Brunet S; Sureda A; Carreras E; Sierra J
Bone Marrow Transplant; 2010 Sep; 45(9):1449-56. PubMed ID: 20140024
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.
Hamad N; Shanavas M; Michelis FV; Uhm J; Gupta V; Seftel M; Kuruvilla J; Lipton JH; Messner HA; Kim DD
Am J Hematol; 2015 May; 90(5):392-9. PubMed ID: 25615933
[TBL] [Abstract][Full Text] [Related]
19. Delayed neutrophil engraftment in cord blood transplantation with intensive administration of mycophenolate mofetil for GVHD prophylaxis.
Okamura A; Shimoyama M; Ishii S; Wakahashi K; Asada N; Kawano H; Kawamori Y; Nishikawa S; Minagawa K; Katayama Y; Matsui T
Bone Marrow Transplant; 2011 Jan; 46(1):148-9. PubMed ID: 20228852
[No Abstract] [Full Text] [Related]
20. Graft-versus-host disease (GVHD) prophylaxis by using methotrexate decreases pre-engraftment syndrome and severe acute GVHD, and accelerates engraftment after cord blood transplantation.
Iguchi A; Terashita Y; Sugiyama M; Ohshima J; Sato TZ; Cho Y; Kobayashi R; Ariga T
Pediatr Transplant; 2016 Feb; 20(1):114-9. PubMed ID: 26526424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
